



The International Pharmaceutical Excipients Council

Best Practices for European REACH Restriction on Synthetic Polymer Microparticles

for Pharmaceutical Excipients

Version 1
2025

Copyright © 2025 The International Pharmaceutical Excipients Council

This document represents voluntary guidance for the excipient industry and the contents should not be interpreted as regulatory requirements. Alternatives to the approaches in this guide may be used to achieve an equivalent level of assurance for excipient quality.

This guide was created to help companies understand current expectations on this topic and is not intended for use by third party certification bodies to conduct audits or to certify compliance with the guide.


The content of this guide cannot be reproduced without the written authorization of the IPEC Federation Management Body.

FOREWORD

The International Pharmaceutical Excipients Council (IPEC) is an international industry association formed by excipient **manufacturers**, **distributors**, and end-users. At the current writing there are regional pharmaceutical excipient industry associations located in the Americas, Europe, Japan, China, and India. IPEC's objective is to contribute to the international excipient standards development and harmonization, provide information useful for new excipient development and introduction, and offer best practice and guidance concerning excipient development.

IPEC has three major **stakeholder** groups:

1. Excipient manufacturers and distributors, defined as **suppliers** in this document,
2. Medicinal (drug) product manufacturers, defined as *excipient users* in this document, and
3. Public health and regulatory authorities.



This guide is intended to be voluntary, to indicate best practice, and to be globally applicable. However, it should be recognized that the laws and regulations applying to excipients will vary from region to region and country. In addition, the rules and regulations are continually evolving. It is the responsibility of the reader to review the most current version of any applicable regulatory requirement. Versions referenced in the guide were based on versions available at the time the guide was published.

In this guide, pharmaceutical excipient(s) will be referred as excipient(s). This guide may be applied to veterinary medicines, as appropriate and include reference to specific veterinary guidance and regulations.

Throughout the guide, **justification** implies that a decision is made based on scientific, quality and/or regulatory considerations.

This guide offers best practice and guidance for preparing and sharing microparticle data needed to justify certain excipient derogations that could apply to **REACH** restriction of **synthetic** polymer microparticles [1] and offers a streamlined process for ensuring compliance with regulatory requirements for both polymer manufacturers, suppliers and downstream industrial users who are typically drug product manufacturers.

This document should be read in conjunction with:

- The Regulation - Annex XVII of EC 1907/2006 Entry 78 (EU 2023/2055)
- The Guidance - REACH restriction of synthetic polymer microparticles (Entry 78 of Annex XVII REACH, as introduced by Commission Regulation (EU) 2023/2055) –
 - Explanatory Guide Part I - Narrative
 - Explanatory Guide Part II – Q&A
 - Explanatory Guide Part III – Annexes
- The Reporting Requirements - Implementation of the reporting requirements of the REACH restriction on microplastics. Reporting Requirements Final ECHA Apr 2025 v1.1

NOTE: Refer to the “International Pharmaceutical Excipients Council Glossary: General Glossary of Terms and Acronyms” for definitions [2].

Table of Contents (TOC)

ACKNOWLEDGEMENTS	6
1 INTRODUCTION	7
1.1 Purpose	7
1.2 Scope	8
1.3 Principles Adopted	8
2 DEFINITION OF SYNTHETIC POLYMER MICROPARTICLES.....	9
2.1 Key points.....	9
2.2 Data Requirements	13
3 EXCIPIENT SCOPE	15
3.1 Natural Polymers	15
3.2 Water soluble polymers	16
3.3 Polymers without carbon atoms in their structure	17
3.4 Biodegradable Polymers	17
3.5 Use of read-across data in biodegradation and solubility studies	19
4 MEDICINAL PRODUCTS AND DEROGATION	21
5 INFORMATION REQUIREMENTS FOR SUPPLIERS FOR SPM.....	25
5.1 Key Points:	25
6 REPORTING REQUIREMENTS FOR EXCIPIENT MANUFACTURERS AND USERS	26
7 PROVISION OF ADDITIONAL SPM IDENTIFIERS TO ENFORCING AUTHORITIES (Paragraph 13 and 14).....	31
7.1 Key Points:	31
8 PARAGRAPH 15 – DEMONSTRATION OF COMPLIANCE WITH EXEMPTION CRITERIA.....	32
9 REFERENCES	33
ANNEX 1.....	35
Assessment of Excipients for Use in Medicinal Products.....	35

ANNEX 2 Link to legal text.....	37
ANNEX 3 Definitions and Abbreviations.....	38

Table of Tables

Table 1: Regulatory Requirements for Medicinal Products	7
Table 2: Provision of information that supports and/or excludes classification as SPM	10
Table 3: Information to ascertain if an excipient is out of scope of the microparticle regulation and who is responsible for making the decision.....	15
Table 4: Test guidelines, conditions and pass criteria to prove solubility in water	16
Table 5: Test methods permitted.....	18
Table 6: Party responsible for provision of information	25
Table 7: Information from EC guidance	27

Table of Figures

Figure 1: A tablet >5 mm with a continuous solid polymer coating → Not SPM, because the coated particle (tablet) exceeds the size threshold	11
Figure 2: A tablet >5 mm with a coating and internal granules <5 mm made of 100% solid polymer → The coating is not SPM, but the internal granules are SPM	12
Figure 3: A tablet >5 mm with internal granules <5 mm and 100% solid polymer → The internal granules are SPM.....	12
Figure 4: A tablet <5 mm with a continuous solid polymer coating → The coating is SPM, regardless of concentration.....	12
Figure 5: A tablet <5 mm with a coating and core containing 10% solid polymer → Both the coating and the internal polymer are SPM.....	13
Figure 6: Specific Reporting Obligations.....	27

ACKNOWLEDGEMENTS

This guide was developed by representatives of the associations which constitute the IPEC Federation (IPEC). The IPEC Federation greatly appreciates the many hours devoted by the core team of individuals and other contributors listed below, to make this guide available to IPEC members and the broader excipient community. Equally, IPEC extends its thanks to the employers of those same contributors who provided the necessary time and resources, without which, this guide would not be possible.

List of Contributors from IPEC-Americas

Chris Moreton – Finn Britt Consulting

Meera Raghuram – Lubrizol; Chair, IPEC Microparticles Team

Priscilla Zawislak - Roquette

List of Contributors from IPEC Europe

Kevin Hughes – Colorcon

We appreciate the constructive input from members of the ChemLeg team during preparation of this guidance.